News ListMonday January 25, 2010 IPSOGEN Obtains Option to Acquire License on TET2 abnormalities to improve the Diagnosis of Blood-based DisordersIPSOGEN today announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene. The scientific corpus supporting these TET2 patent rights has been developed by a... Category: Leukemia
 Wednesday November 04, 2009 Scientific Publications: Standardised WT1 assay developed by the European LeukemiaNet (ELN) consortiumAn international collaborative study coordinated by the European Leukemia Network (ELN) consortium on standardisation of WT1 testing for risk stratification in Acute Myeloid Leukemia has been published in the November 2009 issue... Category: Leukemia
Monday November 02, 2009 Ipsogen expands its IVD offer in leukemia diagnostic with the CE marking of JAK2 MutaQuant™ and JAK2 MutaSearch™ KitsJAK2 MutaQuant™ and MutaSearch™ Kits are now CE marked! Category: Leukemia
Wednesday September 02, 2009 Next EventsIpsogen is participating to a great number of international congresses. Ipsogen’s team will be happy to meet you and discuss your current needs and find out about Ipsogen’s latest developments. ESH-CML 2009 ESH Eleventh... Category: Leukemia
Wednesday July 15, 2009 Ipsogen further expands its offer in leukemia diagnostic, including two new JAK2 V617F detection kits and a new kit for NPM1 mutations in Acute Myeloid LeukemiaTwo new JAK2 V617F detection kits JAK2 V617F MutaSearchTM Kit: a new multiplatform kit compatible with LightCycler® 1.2 & 1.5 systems In order to better address laboratory needs, IPSOGEN developed a new JAK2 V617F detection... Category: Leukemia
Monday May 04, 2009 Ipsogen expands its US market presence through licensing agreement with ARUP Laboratories for the commercialization of JAK2 molecular diagnostic assaysMarseille, France, May 4, 2009 - IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and... Category: Leukemia
Monday April 20, 2009 Ipsogen further expands its offer in leukemia diagnostic, including a new NPM1 kit and 3 new BCR-ABL productsA new kit for NPM1 mutation A in AML NPM1 mutations are involved in about 60% of Acute Myeloid Leukemia (AML) patients with normal karyotype and represent the most specific and frequent genetic lesions described in adult de novo... Category: Leukemia
Sunday March 15, 2009 Ipsogen announces the CE marking of its “ProfileQuant® WT1” kitWT1 is a valuable biomarker in the prognosis and follow-up of Acute Myeloid Leukemia (AML) patients.The ProfileQuant® WT1 kit was developed and validated in the context of an international collaborative study coordinated by the... Category: Leukemia
Monday January 12, 2009 In 2008, Ipsogen reinforced its leadership in molecular diagnosis and monitoring of leukemiaDuring the last quarter of 2008, Ipsogen launched three new molecular diagnostic kits Category: Leukemia
Saturday October 04, 2008 Ipsogen expands its U.S. market presence through licensing agreement with Quest DiagnosticsMarseille, France, October 6th, 2008 Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and... Category: Leukemia, Investors
 |
|
